Using a digital assessment of multi‐day learning curves to detect preclinical AD

Unsupervised remote digital cognitive assessment makes frequent testing feasible and allows for measurement of learning across days on participants’ own devices. More rapid detection of diminished learning may provide a potentially valuable metric for clinical trials seeking to capture change over shorter intervals. Here, we assess whether clinically normal (CN) participants differ in their learning of the same stimuli across daily exposures depending on their β‐amyloid (Aβ) burden.